This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

NMDA receptor antagonists for neuropathic pain

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

N-methyl-d-aspartate (NMDA) receptor antagonists (e.g. ketamine, dextromethorphan, memantine, and amantadine) may have a role in the management of neuropathic pain. These agents are increasingly used by specialists who manage neuropathic pain e.g. in pain clinics and specialist palliative care clinics.

  • Ketamine is generally used as an anaesthetic
    • however at sub-anaesthetic doses it acts as an analgesic by blocking the NMDA receptor in the dorsal horn
    • the NMDA receptor is thought to be activated in clinical states where hyperanalgesia and allodynia are present
    • often ketamine is administered parenterally

Reference:

  1. GP (July 5th 2004), 45-6.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.